… prostate-cancer/ 4. FDA approves new prostate cancer imaging agent Gozellix. News release. Telix Pharmaceuticals … men with prostate cancer: a randomized clinical trial. JAMA Netw … the Oncologic Drugs Advisory Committee. US Food & Drug Administration. …

In this segment, the panel outlines the complementary roles of urologists and radiation oncologists in recommending, evaluating, and placing rectal spacers for prostate cancer radiotherapy. The discussion emphasizes that urologists typically lead …

… of Teverelix, a prostate cancer drug candidate acquired through its … site selection strategies and pharmacodynamic-informed patient stratification, … Phase 2 clinical trial of its SkinJect program … containing microneedle arrays to treat basal cell carcinoma. …

… pharmacodynamic data, we aim to support more precise trial … to non-invasively treat basal cell carcinoma … #39;s flagship drug candidate is Teverelix … treatment for advanced prostate cancer patients with increased cardiovascular risk. In December 2023, FDA …

… An upcoming combination trial with irinotecan in … safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with … treatments for patients with advanced castration-resistant prostate cancer, … inhibitors. Biosplice’s drugs in clinical development …

… Care Managing prostate cancer requires more than the right medications and … screening, diagnostics, treatments and psychosocial support. Prostate cancer treatment requires a multidisciplinary team … early so we can treat it effectively. Give yourself …

… Trial allowed us to do just that, by harnessing two immunotherapy drugs … prostate cancer. The EVOLUTION clinical trial has shown that adding nuclear medicine treatment … resistant prostate cancer – one of the most challenging forms of prostate cancer to treat. …

… Phase 3 trial results for Illuccix (TLX591-CDx) in Chinese prostate cancer patients … -term New Drug Application (NDA) submission in China. FDA resubmission for … keeping treatment options open for eligible patients. What did Telix Pharmaceuticals management …

… with biochemical recurrence of prostate cancer following surgery or radiation … a change in their treatment plan following scanning. … partner Grand Pharma to submit a New Drug Application … demonstrate comparability between clinical trial material and scaled- …

… collaborative interactions with the FDA, finalizing NDA resubmission … prostate cancer imaging in Chinese patients. The Illuccix China2 trial … leading to improved treatment strategies for participants with … Grand Pharma to submit a New Drug Application …